Anti-Müllerian hormone is associated with extrauterine involvement and stage of disease in patients with endometrial cancer

References

• Aksglaede L, Sorensen K, Boas M, Mouritsen A, Hagen CP, Jensen RB et al. 2010. Changes in anti-Mullerian hormone (AMH) throughout the life span: a population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. Journal of Clinical Endocrinology and Metabolism 95:5357–5364.
   PubMed Web of Science ®Google Scholar
• Antonsen SL, Jensen LN, Loft A, Berthelsen AK, Costa J, Tabor A et al. 2013. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer – a multicenter prospective comparative study. Gynecologic Oncology 128:300–308.
   PubMed Web of Science ®Google Scholar
• Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I et al. 2008. Mullerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecologic Oncology 108:141–148.
   PubMed Web of Science ®Google Scholar
• Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. 2003. Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proceedings of the National Academy of Sciences of the United States of America 100:15601–15606.
   PubMed Web of Science ®Google Scholar
• Celik C, Ozdemir S, Kiresi D, Emlik D, Tazegul A, Esen H. 2010. Evaluation of cervical involvement in endometrial cancer by transvaginal sonography, magnetic resonance imaging and frozen section. Journal of Obstetrics and Gynaecology 30:302–307.
   Web of Science ®Google Scholar
• Chang HL, Pieretti-Vanmarcke R, Nicolaou F, Li X, Wei X, MacLaughlin DT et al. 2011. Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecologic Oncology 120:128–134.
   PubMed Web of Science ®Google Scholar
• Dutertre M, Gouedard L, Xavier F, Long WQ, Di Clemente N, Picard JY et al. 2001. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology 142:4040–4046.
   PubMed Web of Science ®Google Scholar
• Fischerova D, Frühauf F, Zikan M, Pinkavova I, Kocián R, Dundr P et al. 2014. Factors affecting preoperative local staging of endometrial cancer. Ultrasound in Obstetrics and Gynecology 43:575–585.
   PubMed Web of Science ®Google Scholar
• Gürgen SG, Gürgen O, Kirkim G, Kolatan HE, Gürkan S, Eskiizmir, G. 2013. The effect of erythropoietin on S100 protein expression in cochlea after acoustic overstimulation: an experimental study. Journal of Clinical and Analytical Medicine. Available at: http://www.jcam.com.tr/files/KATD-2009.pdf (Accessed 14 July 2014).
   Google Scholar
• Hirobe S, He WW, Gustafson ML, MacLaughlin DT, Donahoe PK. 1994. Mullerian inhibiting substance gene expression in the cycling rat ovary correlates with recruited or Graafian follicle selection. Biology of Reproduction 50:1238–1243.
   PubMed Web of Science ®Google Scholar
• Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM et al. 2003. Mullerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Molecular and Cellular Endocrinology 211:43–49.
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Suh MJ, Yoon JH, Kim MR, Ryu KS, Nam SW et al. 2011. Identification of characteristic molecular signature of Mullerian inhibiting substance in human HPV-related cervical cancer cells. International Journal of Oncology 39:811–820.
   PubMed Web of Science ®Google Scholar
• La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. 2009. Anti-Mullerian hormone (AMH): what do we still need to know? Human Reproduction 24:2264–2275.
   PubMed Web of Science ®Google Scholar
• Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF et al. 2006. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 103:17426–17431.
   PubMed Web of Science ®Google Scholar
• Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. 2005. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proceedings of the National Academy of Sciences of the United States of America 102:111–116.
   PubMed Web of Science ®Google Scholar
• Rey R, Sabourin JC, Venara M, Long WQ, Jaubert F, Zeller WP et al. 2000. Anti-Mullerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Human Pathology 31:1202–1208.
   PubMed Web of Science ®Google Scholar
• Song JY, Jo HH, Kim MR, Lew YO, Ryu KS, Cha JH et al. 2012. Expression of Mullerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer. International Journal of Oncology 40:2013–2021.
   PubMed Web of Science ®Google Scholar
• Stephen AE, Masiakos PT, Segev DL, Vacanti JP, Donahoe PK, MacLaughlin DT. 2001. Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo. Proceedings of the National Academy of Sciences of the United States of America 98:3214–3219.
   PubMed Web of Science ®Google Scholar
• Walentowicz P, Sadlecki P, Krintus M, Sypniewska G, Mankowska-Cyl A, Grabiec M. 2013. Serum anti-mullerian hormone levels in patients with epithelial ovarian cancer. International Journal of Endocrinology 2013:517239.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Roffler SR, Chou HH, Yin FY, Yin CS. 1994. Characterization of mullerian inhibiting substance binding on cervical carcinoma cells demonstrated by immunocytochemistry. Tissue and Cell 26:467–476.
   PubMed Web of Science ®Google Scholar
• Wang PY, Koishi K, McGeachie AB, Kimber M, MacLaughlin DT, Donahoe PK et al. 2005. Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proceedings of the National Academy of Sciences of the United States of America 102:16421–16425.
   PubMed Web of Science ®Google Scholar